Seq, a CRISPR-based method that enriches ultra-rare tumor DNA in blood by removing background wild-type DNA before sequencing ...
MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can ...
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...
This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...
Why Do Large B-Cell Lymphoma Patients With High Tumor Mutation Burden Relapse on CAR T-Cell Therapy?
Researchers explored this question at ASH and shared data suggesting genomic instability in tumors with high TMB likely enables them to hide from immune attack.
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...
The global genomics market is set to expand from USD 47.07 billion in 2025 to USD 85.09 billion by 2030, with a CAGR of 12.6% ...
Cell free RNA diagnostics market is projected to reach US$ 204.5 Mn by 2035, expanding at a CAGR of 14.5% from 2025 to 2035 ...
The next generation sequencing market offers significant opportunities by enhancing the diagnosis and treatment of chronic ...
Spatial RNA medicine combines transcriptomics and RNA therapeutics, mapping gene expression in tissues to enhance precision ...
From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback